目的：探讨趋化因子CXCL12 及其受体CXCR4、CXCR7 在乳腺癌组织中的表达及临床意义。 方法： 应用qRT-PCR 方法检测35 例新鲜乳腺癌组织及癌旁正常乳腺组织中CXCL12 及其受体 CXCR4、CXCR7 的mRNA 表达，采用免疫组化检测120 例乳腺癌细胞组织石蜡标本中CXCL12 及其 受体CXCR4、CXCR7 的蛋白表达，并分析三者的表达与患者临床特征的关系。 结果：qRT-PCR 结果显示，CXCL12、CXCR4、CXCR7 的mRNA 在乳腺癌组织中表达量均明显高于癌 旁正常乳腺组织（均P<0.05）。免疫组化结果显示，CXCL12、CXCR4、CXCR7 蛋白在乳腺癌组织中 阳性表达率分别为70.8%（85/120）、65.8%（79/120）和63.3%（76/120），三者在均在伴有淋巴结 转移及TNM 分期较高的患者乳腺癌组织中表达明显升高（均P<0.05）。 结论：趋化因子CXCL12 及其受体CXCR4、CXCR7 的高表达可能与乳腺癌淋巴转移及恶性进展密切 相关。
Expression and clinical significance of chemokine CXCL12 with its receptor CXCR4 and CXCR7 in human breast cancer tissue
Objective: To investigate the expressions of chemokine CXCL12 as well as its receptor CXCR4 and CXCR7 in breast cancer tissue and the clinical significance. Methods: The mRNA expressions of CXCL12, CXCR4 and CXCR7 were determined by qRT-PCR method in fresh specimens of breast cancer tissue and their adjacent normal breast tissue from 35 patients. The protein expressions of CXCL12, CXCR4 and CXCR7 were detected by immunohistochemical staining in 120 paraffinembedded samples of breast cancer tissue, and the relations of their expressions with clinicopathologic features of breast cancer were analyzed. Results: Results of qRT-PCR showed that the mRNA expression levels of CXCL12, CXCR4 and CXCR7 in breast cancer tissue were all significantly higher than those in adjacent normal breast tissue (all P<0.05). Results of immunohistochemical staining showed that the positive expression rate of CXCL12, CXCR4 and CXCR7 in breast carcinoma tissues was 70.8%, 65.8% and 63.3% respectively, and the positive expression rate of either protein was significantly increased in breast cancer tissue from those with lymph node metastasis or advanced TNM stage (all P<0.05). Conclusion: The high expressions of chemokine CXCL12 as well as its receptor CXCR4 and CXCR7 may be closely associated with the lymph node metastasis and malignant progression of breast cancer.